Objective-To determine the policies applied in genitourinary medicine (GUM) 
There is lack of agreement as to which HBV marker should be included in a prevaccination screen. This should include anti-HBc which should pick up, ideally, patients who have not been exposed to HBV and should be vaccinated. Those who are anti-HBc positive should be further tested for HBsAg to identify HBV carriers and offer them appropriate medical attention.
Postvaccination HB V screen and booster doses WHO stated9 that quantitative evaluation of the immune response after vaccination is desirable in order to identify inadequate responders and non-responders. Anti-HBs should ideally be measured one to three months after completion of the basic course of immunisations. 80% of the genitourinary physicians followed these recommendations and considered anti-HBs titre > 100 miu/ml to be an optimal response to vaccination. An individual with a peak of anti-HBs below 10 miu/ml after the basic course of vaccination probably lacks protection against HBV infection.9 Approximately 5% of healthy individuals under the age of 40 years and up to 50% of individuals with chronic renal failure,'0 alcoholic liver disease," HIV positive patients'2 and the elderly'3 will fail to mount a sufficient anti-body response. Individuals with peak anti-HBs levels of 10-100 miu/ml (suboptimal response) generally lack detectable antiHBs within one year. Suboptimal responders (anti-HBs 10-100 miu/ml) and non-responders (anti-HBs < 10 miu/ml) should be considered for a booster dose or, possibly, for a repeat course of vaccine. After a good response (> 100 miu/ml) to a vaccination course, the length of protection remains 
